AGL 38.31 Decreased By ▼ -0.25 (-0.65%)
AIRLINK 215.00 Increased By ▲ 7.23 (3.48%)
BOP 10.06 No Change ▼ 0.00 (0%)
CNERGY 6.77 Decreased By ▼ -0.31 (-4.38%)
DCL 9.85 Decreased By ▼ -0.14 (-1.4%)
DFML 40.89 Decreased By ▼ -0.25 (-0.61%)
DGKC 101.94 Decreased By ▼ -1.52 (-1.47%)
FCCL 36.35 No Change ▼ 0.00 (0%)
FFBL 91.22 Decreased By ▼ -0.37 (-0.4%)
FFL 14.10 Decreased By ▼ -0.50 (-3.42%)
HUBC 136.90 Decreased By ▼ -2.53 (-1.81%)
HUMNL 14.00 Decreased By ▼ -0.10 (-0.71%)
KEL 5.87 Decreased By ▼ -0.10 (-1.68%)
KOSM 7.38 Decreased By ▼ -0.48 (-6.11%)
MLCF 46.98 Decreased By ▼ -0.30 (-0.63%)
NBP 66.38 Decreased By ▼ -7.38 (-10.01%)
OGDC 221.45 Decreased By ▼ -1.21 (-0.54%)
PAEL 38.05 Decreased By ▼ -0.06 (-0.16%)
PIBTL 9.05 Decreased By ▼ -0.22 (-2.37%)
PPL 204.50 Decreased By ▼ -1.35 (-0.66%)
PRL 39.60 Decreased By ▼ -0.25 (-0.63%)
PTC 26.20 Decreased By ▼ -0.42 (-1.58%)
SEARL 107.25 Decreased By ▼ -2.99 (-2.71%)
TELE 9.04 Decreased By ▼ -0.19 (-2.06%)
TOMCL 37.90 Decreased By ▼ -0.31 (-0.81%)
TPLP 13.69 Decreased By ▼ -0.08 (-0.58%)
TREET 26.10 Decreased By ▼ -0.35 (-1.32%)
TRG 59.68 Decreased By ▼ -0.86 (-1.42%)
UNITY 33.50 Decreased By ▼ -0.64 (-1.87%)
WTL 1.77 Decreased By ▼ -0.11 (-5.85%)
BR100 12,165 Decreased By -133.6 (-1.09%)
BR30 38,276 Decreased By -601.6 (-1.55%)
KSE100 113,422 Decreased By -1438.9 (-1.25%)
KSE30 35,728 Decreased By -467.5 (-1.29%)

ROME: A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca’s coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday.

Marco Cavaleri, the EMA’s head of vaccine strategy, also told Italy’s La Stampa newspaper that the Johnson & Johnson jab should be preferentially used for the over 60s.

Both so-called viral vector vaccines are authorised for everyone over 18 but have been dogged by reports of rare blood clots. The EU has also authorised two mRNA vaccines, Pfizer/BioNTech and Moderna.

Italy on Saturday restricted AstraZeneca vaccines to people aged 60 and over following concerns about the heightened health risks for younger people.

Asked if it would not be better to ban AstraZeneca including for the over 60s, Cavaleri said: “Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines.

“However, incidents were very rare and after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well.”

He added: “Among young people the risks of illness decrease, and the message for them could be to use preferentially the mRNA vaccines, but the choice is left to individual states.”

Comments

Comments are closed.